Somatrogon: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Somatrogon. Educational only — not medical advice.
Labeled uses
NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
Source: FDA labeling via NIH DailyMed (set 06dce529…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.